Clinical Trials
9 trialsNCT02869217 2025-12-03
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
University Health Network, Toronto
Phase 1 Active not recruiting
NCT05400122 2025-11-12
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Case Comprehensive Cancer Center
Phase 1 Suspended
NCT06532799 2024-11-12
BAH250
Essen Biotech
Phase 1/2 Recruiting
NCT02096614 2021-06-18
Investigator Initiated Phase 1 Study of TBI-1201
Mie University
Phase 1 Completed
NCT02757391 2020-10-30
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02366546 2018-10-24
Investigator Initiated Phase 1 Study of TBI-1301
Mie University
Phase 1 Unknown
NCT01795976 2018-08-07
ATTACK-OG
The Christie NHS Foundation Trust
Phase 2 Terminated
NCT02457650 2016-08-03
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies
Shenzhen Second People's Hospital
Phase 1 Unknown
NCT00002854 2015-08-26
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
City of Hope Medical Center
Phase 1 Completed